Novavax (Germany) Today
| NVV1 Stock | EUR 5.93 0.04 0.67% |
PerformanceInsignificant
| Odds Of DistressAverage
|
Novavax is trading at 5.93 as of the 19th of July 2025. This is a 0.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.93. Novavax has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. The company has 85 M outstanding shares. More on Novavax
Moving against Novavax Stock
Novavax cannot be verified against its exchange. Apparently, Novavax is not available for investing at the moment. Please verify the symbol is currently traded on Frankfurt Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
RefreshNovavax Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novavax's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novavax or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Stanley Erck |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Novavax (NVV1) is traded on Frankfurt Exchange in Germany and employs 1,541 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 727.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novavax's market, we take the total number of its shares issued and multiply it by Novavax's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novavax operates under Healthcare sector and is part of Biotechnology industry. The entity has 85 M outstanding shares.
Novavax has accumulated about 1.57 B in cash with 322.95 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.11.
Check Novavax Probability Of Bankruptcy
Novavax Risk Profiles
Although Novavax's alpha and beta are two of the key measurements used to evaluate Novavax's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.4 | |||
| Semi Deviation | 3.65 | |||
| Standard Deviation | 4.96 | |||
| Variance | 24.63 |
Novavax Stock Against Markets
Try Other Suggestions
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novavax without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Novavax Corporate Management
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS | Exec Officer | Profile | |
| Jody Lichaa | Senior Vice President - Quality Assurance | Profile | |
| Ben Machielse | Executive Vice President - CMC | Profile | |
| Michael McManus | Independent Director | Profile | |
| Brian Webb | Senior Vice President - Manufacturing | Profile |
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.